# Knowledge gaps and research priorities to understand sex differences in immunity

**Authors:** Katie L. Flanagan, Sabra L. Klein

PMC · DOI: 10.1371/journal.pbio.3003578 · PLOS Biology · 2026-02-02

## TL;DR

This paper discusses how immunity differs between males and females, and highlights the need for more research to understand these differences and improve sex-specific treatments.

## Contribution

The paper identifies key research priorities to uncover the mechanisms behind sex differences in immunity.

## Key findings

- Sex differences in immunity affect disease susceptibility and treatment responses.
- Research is needed to understand the cellular and signaling pathways behind these differences.
- Knowledge of sex-specific immune mechanisms can lead to better tailored treatments.

## Abstract

Differences in immunity in males and females throughout the life span manifest as differences in susceptibility to chronic diseases, infections, cancer, and responses to therapeutic interventions such as immunomodulatory drugs and vaccines. Sex steroids and sex chromosome-linked immune response genes have major roles in driving these differences, but the cells and signaling pathways governing these are disease-specific and often not known. Such knowledge is required to better understand sex differences in disease incidence and clinical course, and to provide treatments tailored to sex-divergent pathways underlying specific diseases. This Essay explores the major areas where further research is required to determine sex-differential mechanisms.

Immunity differs profoundly according to biological sex, leading to sex differences in autoimmunity, infections, cancer and responses to immunotherapy and vaccines. This Essay explores the major areas where further research is required to determine sex-differential mechanisms in immunity.

## Linked entities

- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Genes:** IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, JUN (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3725] {aka AP-1, AP1, c-Jun, cJUN, p39}, TLR2 (toll like receptor 2) [NCBI Gene 7097] {aka CD282, TIL4}, RIEG2 (Rieger syndrome 2) [NCBI Gene 6012] {aka ARS, RGS2}, IFNA1 (interferon alpha 1) [NCBI Gene 3439] {aka IFL, IFN, IFN-ALPHA, IFN-alphaD, IFNA13, IFNA@}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, MIR221 (microRNA 221) [NCBI Gene 407006] {aka MIRN221, miRNA221, mir-221}, KDM6A (lysine demethylase 6A) [NCBI Gene 7403] {aka KABUK2, UTX, bA386N14.2}, TSPY1 (testis specific protein Y-linked 1) [NCBI Gene 7258] {aka CT78, DYS14, TSPY, pJA923}, DDX3X (DEAD-box helicase 3 X-linked) [NCBI Gene 1654] {aka CAP-Rf, DBX, DDX14, DDX3, HLP2, MRX102}, IL9R (interleukin 9 receptor) [NCBI Gene 3581] {aka CD129, IL-9R}, MIR92B (microRNA 92b) [NCBI Gene 693235] {aka MIRN92B, hsa-mir-92b, mir-92b}, TLR4 (toll like receptor 4) [NCBI Gene 7099] {aka ARMD10, CD284, TLR-4, TOLL}, CD99 (CD99 molecule (Xg blood group)) [NCBI Gene 4267] {aka HBA71, MIC2, MIC2X, MIC2Y, MSK5X}, CSF2RA (colony stimulating factor 2 receptor subunit alpha) [NCBI Gene 1438] {aka CD116, CDw116, CSF2R, CSF2RAX, CSF2RAY, CSF2RX}, KDM5D (lysine demethylase 5D) [NCBI Gene 8284] {aka HY, HYA, JARID1D, SMCY}, MIR21 (microRNA 21) [NCBI Gene 406991] {aka MIRN21, hsa-mir-21, miR-21, miRNA21}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CD79A (CD79a molecule) [NCBI Gene 973] {aka IGA, IGAlpha, MB-1, MB1}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, ESR2 (estrogen receptor 2) [NCBI Gene 2100] {aka ER-BETA, ESR-BETA, ESRB, ESTRB, Erb, NR3A2}, XIST (X inactive specific transcript) [NCBI Gene 7503] {aka DXS1089, DXS399E, LINC00001, NCRNA00001, SXI1, swd66}, EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}, ELK1 (ETS transcription factor ELK1) [NCBI Gene 2002], TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, TLR7 (toll like receptor 7) [NCBI Gene 51284] {aka IMD74, SLEB17, TLR7-like}, RBMY1A1 (RNA binding motif protein Y-linked family 1 member A1) [NCBI Gene 5940] {aka RBM, RBM1, RBM2, RBMY, RBMY1C, YRRM1}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, TLR8 (toll like receptor 8) [NCBI Gene 51311] {aka CD288, IMD98, TLR-8, hTLR8}, CD40LG (CD40 ligand) [NCBI Gene 959] {aka CD154, CD40L, HIGM1, IGM, IMD3, T-BAM}, IRAK1 (interleukin 1 receptor associated kinase 1) [NCBI Gene 3654] {aka IRAK, pelle}, DIAPH2-AS1 (DIAPH2 antisense RNA 1) [NCBI Gene 10824] {aka EPAG}, IL2RG (interleukin 2 receptor subunit gamma) [NCBI Gene 3561] {aka CD132, CIDX, IL-2RG, IMD4, P64, SCIDX}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, CXCR3 (C-X-C motif chemokine receptor 3) [NCBI Gene 2833] {aka CD182, CD183, CKR-L2, CMKAR3, GPR9, IP10-R}, SMAD7 (SMAD family member 7) [NCBI Gene 4092] {aka CRCS3, MADH7, MADH8}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, NOS3 (nitric oxide synthase 3) [NCBI Gene 4846] {aka EC-NOS, ECNOS, MYMY8, NOSIII, cNOS, eNOS}, BTK (Bruton tyrosine kinase) [NCBI Gene 695] {aka AGMX1, AT, ATK, BPK, IGHD3, IMD1}, GUSB (glucuronidase beta) [NCBI Gene 2990] {aka BG, MPS7}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, ESR1 (estrogen receptor 1) [NCBI Gene 2099] {aka ER, ESR, ESRA, ESTRR, Era, NR3A1}, SASH3 (SAM and SH3 domain containing 3) [NCBI Gene 54440] {aka 753P9, CXorf9, HACS2, IMD102, SH3D6C, SLY}, MIR223 (microRNA 223) [NCBI Gene 407008] {aka MIRN223, miRNA223, mir-223}, LAMP2 (lysosome associated membrane protein 2) [NCBI Gene 3920] {aka CD107b, DND, LAMP-2, LAMPB, LGP-96, LGP110}, FOXP3 (forkhead box P3) [NCBI Gene 50943] {aka AIID, DIETER, IPEX, JM2, PIDX, XPID}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, MIR214 (microRNA 214) [NCBI Gene 406996] {aka MIRN214, miRNA214, mir-214}, CYBB (cytochrome b-245 beta chain) [NCBI Gene 1536] {aka AMCBX2, CGD, CGDX, GP91-1, GP91-PHOX, GP91PHOX}, RNPC3 (RNA binding region (RNP1, RRM) containing 3) [NCBI Gene 55599] {aka CPHD7, IGHD5, RBM40, RNP, SNRNP65}
- **Diseases:** infections (MESH:D007239), Crohn's disease (MESH:D003424), Autoimmune diseases (MESH:D001327), Turner syndrome (MESH:D014424), splenomegaly (MESH:D013163), primary biliary cirrhosis (MESH:D008105), cutaneous lupus (MESH:D008178), nonsmall cell lung cancer (MESH:D002289), autoimmune thyroid disease (MESH:D013967), GAHT (MESH:D019968), linked (MESH:C536424), cancer (MESH:D009369), hepatocellular carcinoma (MESH:D006528), Infectious diseases (MESH:D003141), melanoma (MESH:D008545), rheumatoid arthritis (MESH:D001172), hepatitis B and C (MESH:D006509), experimental allergic encephalomyelitis (MESH:D004681), measles (MESH:D008457), myocarditis (MESH:D009205), systemic sclerosis (MESH:D012595), SLE (MESH:D008180), tuberculosis (MESH:D014376), Klinefelter (MESH:D007713), gastric cancer (MESH:D013274), Hodgkin's lymphoma (MESH:D006689), COVID-19 (MESH:D000086382), MHT (MESH:D008594), yellow fever (MESH:D015004), viral, bacterial, parasitic, and fungal infections (MESH:D014777), influenza A infection (MESH:D007251), type 1 diabetes (MESH:D003922), prostate cancer (MESH:D011471), hematological malignancies (MESH:D019337), myelodysplastic syndrome (MESH:D009190), dysbiosis (MESH:D064806), myeloproliferative (MESH:D009196), lupus nephritis (MESH:D008181), multiple sclerosis (MESH:D009103), colorectal and prostate cancer (MESH:D015179), ankylosing spondylitis (MESH:D013167), inflammation (MESH:D007249), Sjogren syndrome (MESH:D012859), breast cancer (MESH:D001943)
- **Chemicals:** chloroquine (MESH:D002738), rapamycin (MESH:D020123), BioRender (-), nitric oxide (MESH:D009569), Estradiol (MESH:D004958), dihydrotestosterone (MESH:D013196), Testosterone (MESH:D013739), steroid (MESH:D013256), progesterone (MESH:D011374), alcohol (MESH:D000438), everolimus (MESH:D000068338), lipopolysaccharide (MESH:D008070)
- **Species:** Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395], Actinomycetota (actinobacteria, phylum) [taxon 201174], Prevotella (genus) [taxon 838], Eubacteriales (order) [taxon 186802], Rattus norvegicus (brown rat, species) [taxon 10116], Mus musculus (house mouse, species) [taxon 10090], Clostridium (genus) [taxon 1485], Homo sapiens (human, species) [taxon 9606], Ruminococcus (genus) [taxon 1263], Bifidobacterium longum subsp. infantis (subspecies) [taxon 1682], gut metagenome (species) [taxon 749906], Bacillota (clostridial firmicutes, phylum) [taxon 1239]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12863523/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12863523/full.md

## References

155 references — full list in the complete paper: https://tomesphere.com/paper/PMC12863523/full.md

---
Source: https://tomesphere.com/paper/PMC12863523